PTC Therapeutics, Inc. Payments of Debt Issuance Costs
PTC Therapeutics, Inc. (PTCT) reported Payments of Debt Issuance Costs of $13.75 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtIssuanceCosts · last filed 2026-07-30
- PTC Therapeutics, Inc. payments of debt issuance costs for the quarter ending 2023-12-31 was $0.00.
- PTC Therapeutics, Inc. payments of debt issuance costs for the quarter ending 2023-09-30 was $85.00K.
- PTC Therapeutics, Inc. payments of debt issuance costs for the quarter ending 2023-06-30 was $15.00K.
- PTC Therapeutics, Inc. payments of debt issuance costs for the quarter ending 2023-03-31 was $182.00K.
- PTC Therapeutics, Inc. payments of debt issuance costs for fiscal 2023 was $282.00K, a 97.54% decline from fiscal 2022.
- PTC Therapeutics, Inc. payments of debt issuance costs for fiscal 2022 was $11.45M.
- PTC Therapeutics, Inc. payments of debt issuance costs for fiscal 2019 was $0.00.
- PTC Therapeutics, Inc. payments of debt issuance costs for fiscal 2018 was $0.00, a 100.00% decline from fiscal 2017.
| Period end | Payments of Debt Issuance Costs 3 month | Payments of Debt Issuance Costs 6 month | Payments of Debt Issuance Costs 9 month | Payments of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2026-06-30 | $13.75M 10-Q · filed 2026-07-30 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $85.00K derived: sum of 2 quarters · filed 2026-02-19 | $100.00K derived: sum of 3 quarters · filed 2026-02-19 | $282.00K 10-K · filed 2026-02-19 |
| 2023-09-30 | $85.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $100.00K derived: sum of 2 quarters · filed 2024-11-07 | $282.00K 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $15.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $197.00K 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $182.00K 10-Q · filed 2024-04-25 | |||
| 2022-12-31 | $11.45M 10-K · filed 2025-02-27 | |||
| 2019-12-31 | $0.00 10-K · filed 2020-03-02 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $0.00 derived: sum of 2 quarters · filed 2020-03-02 | $0.00 10-K · filed 2020-03-02 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | $0.00 10-Q · filed 2018-11-05 | ||
| 2018-06-30 | $0.00 10-Q · filed 2018-08-07 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $0.00 derived: sum of 2 quarters · filed 2020-03-02 | $432.00K 10-K · filed 2020-03-02 | |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | $432.00K 10-Q · filed 2018-11-05 | ||
| 2017-06-30 | $432.00K 10-Q · filed 2018-08-07 | |||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $0.00 derived: sum of 2 quarters · filed 2019-03-01 | $0.00 10-K · filed 2019-03-01 | |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $0.00 10-Q · filed 2017-11-02 | ||
| 2016-06-30 | $0.00 10-Q · filed 2017-08-09 | |||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $4.65M 10-K · filed 2017-03-16 | ||
| 2015-09-30 | $4.65M 10-Q · filed 2016-11-03 | |||
| 2014-12-31 | $0.00 10-K · filed 2017-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |